Other languages Arch Therapeutics, Inc.

Equities

ARTH

US03939W2089

Market Closed - OTC Markets Other stock markets 12:36:29 2024-04-22 pm EDT			5-day change	1st Jan Change
1.18 ^USD	+12.38%		+4.42%	-83.70%

Feb. 20	Arch Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	CI
Feb. 15	Arch Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Arch Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 20
Arch Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Feb. 15
Arch Therapeutics, Inc. to Present AC5®? Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)	Nov. 02
Arch Therapeutics, Inc. Provides Commercialization Update on the First Product, AC5 Advanced Wound System	23-09-13
Arch Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-11
Arch Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-23
Arch Therapeutics to Present AC5(R) Advanced Wound System At 2023 Symposium on Advanced Wound Care	23-04-25
Arch Therapeutics, Inc. Announces Dedicated HCPCS Billing Code for its Advanced Wound System Now in Effect	23-04-05
Arch Therapeutics' AC5(R) Advanced Wound System Receives Dedicated HCPCS Billing Code from the Centers for Medicare & Medicaid Services	23-03-09
Arch Therapeutics Announces Addition of Contract Sales Force to Advance Commercialization of Ac5® Advanced Wound System in Government Facilities	23-03-07
Arch Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	23-02-14
Arch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound System	23-01-18
Arch Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	22-12-28
Arch Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	22-12-27
Arch Therapeutics Announces First Shipments of Ac5® Advanced Wound System Under New Reimbursement Support Program	22-09-23
Arch Therapeutics, Inc. Launches Multi-Site Clinical Study for AC5® Advanced Wound System	22-09-07
Arch Therapeutics, Inc. Submits Application to Centers for Medicare and Medicaid Services for Ac5® Advanced Wound System	22-09-01
Arch Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	22-08-11
Arch Therapeutics, Inc. Provides Update on Reimbursement Strategy in Additional Selling Channel	22-06-22
Arch Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022	22-05-13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Arch Therapeutics, Inc.

Equities

ARTH

US03939W2089

Other languages

Filters